Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial

The Lancet Oncology

Volumn 17, Issue 8, 2016, Pages 1061-1069

  Incrocci, Luca ^a   Wortel, Ruud C ^a   Alemayehu, Wendimagegn Ghidey ^a   Aluwini, Shafak ^a   Schimmel, Erik ^b   Krol, Stijn ^c   van der Toorn, Peter Paul ^d   Jager, Hanja de ^e   Heemsbergen, Wilma ^f   Heijmen, Ben ^a   Pos, Floris ^f  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b Institute for Radiation Oncology   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d CATHARINA HOSPITAL   (Netherlands)

^e Radiotherapy Centre West   (Netherlands)

^f ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CONTROLLED STUDY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; TREATMENT DURATION; TREATMENT FAILURE; CANCER GRADING; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; INTENSITY MODULATED RADIATION THERAPY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROCEDURES; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; DOSE HYPOFRACTIONATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84995968150     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30070-5     Document Type: Article

References (25)

1. 1 Peeters, ST, Heemsbergen, WD, Koper, PC, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24 (2006), 1990–1996.
2. 2 Dearnaley, DP, Sydes, MR, Graham, JD, et al., on behalf of the RT01 collaborators. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8 (2007), 475–487.
3. 3 Pollack, A, Zagars, GK, Starkschall, G, et al. Prostate cancer radiation dose response: results of the M D Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002), 1097–1105.
4. 4 Peeters, ST, Heemsbergen, WD, van Putten, WL, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 61 (2005), 1019–1034.
5. 5 Dasu, A, Toma-Dasu, I, Prostate alpha/beta revisited: an analysis of clinical results from 14168 patients. Acta Oncol 51 (2012), 963–974.
6. 6 Miralbell, R, Roberts, SA, Zubizarreta, E, Hendry, JH, Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5 969 patients in seven international institutional datasets: alpha/beta=1·4 (0·9–2·2) Gy. Int J Radiat Oncol Biol Phys 82 (2012), e17–e24.
7. 7 Fowler, JF, The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol 44 (2005), 265–276.
8. 8 Brenner, DJ, Martinez, AA, Edmundson, GK, Mitchell, C, Thames, HD, Armour, EP, Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52 (2002), 6–13.
9. 9 Aluwini, S, Pos, F, Schimmel, E, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncol 16 (2015), 274–283.
10. 10 Aluwini, S, Pos, F, Schimmel, E, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol 17 (2016), 464–474.
11. 11 Chism, DB, Hanlon, AL, Horwitz, EM, Feigenberg, SJ, Pollack, A, A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys 59 (2004), 380–385.
12. 12 Partin, AW, Mangold, LA, Lamm, DM, Walsh, PC, Epstein, JI, Pearson, JD, Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58 (2001), 843–848.
13. 13 Partin, AW, Kattan, MW, Subong, EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. JAMA 277 (1997), 1445–1451.
14. 14 Roach, M III, Hanks, G, Thames, H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006), 965–974.
15. 15 Arcangeli, G, Saracino, B, Gomellini, S, et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 78 (2010), 11–18.
16. 16 Arcangeli, S, Strigari, L, Gomellini, S, et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 84 (2012), 1172–1178.
17. 17 Pollack, A, Walker, G, Horwitz, EM, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 31 (2013), 3860–3868.
18. 18 Pollack, A, Hanlon, AL, Horwitz, EM, et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 64 (2006), 518–526.
19. 19 Lukka, H, Hayter, C, Julian, JA, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 23 (2005), 6132–6138.
20. 20 Yeoh, EE, Botten, RJ, Butters, J, Di Matteo, AC, Holloway, RH, Fowler, J, Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase 3 randomized trial. Int J Radiat Oncol Biol Phys 81 (2011), 1271–1278.
21. 21 Yeoh, EE, Holloway, RH, Fraser, RJ, et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 66 (2006), 1072–1083.
22. 22 Vogelius, IR, Bentzen, SM, Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news?. Int J Radiat Oncol Biol Phys 85 (2013), 89–94.
23. 23 Wilkins, A, Mossop, H, Syndikus, I, et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 16 (2015), 1605–1616.
24. 24 Dearnaley, D, Syndikus, I, Sumo, G, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 13 (2012), 43–54.
25. 25 Dearnaley, D, Syndikus, I, Mossop, H, et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. Eur J Cancer, 51(suppl S3), 2015, S712.